Compare Nutanix Inc (NTNX) vs Oscar Health Inc (OSCR) Price & Performance

Nutanix (NTNX) trades at $67.49, down 0.84% on the day, but maintains a bullish technical outlook with strong support near $66. The company reported robust Q4 2026 earnings, beating EPS estimates with $0.60 versus $0.49 expected, and revenue growth continues to accelerate. Analyst sentiment is overwhelmingly positive with a consensus price target of $77.20 and no sell ratings among 32 analysts covering the stock.

The outlook remains favorable given consistent earnings beats and recognition in Gartner's Magic Quadrant. Key risks include high valuation multiples like EV/EBITDA of 50.5 and competitive pressures in cloud infrastructure. The stock offers upside to consensus targets but requires monitoring of execution against growth expectations.

Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.

Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.